Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism

References

• Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg 2009;91:636-44
   Web of Science ®Google Scholar
• Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. J Clin Pharmacol Therapeut 2005;78:412-21
   Google Scholar
• Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• van Bellen B, Prins M, Bamber L, et al. Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Atlanta, GA: American Society of Hematology [Poster presentation], 2012. https://ash.confex.com/ash/2012/webprogram/Paper51519.html. Accessed December 10, 2012
   Google Scholar
• Killeen M, Hughes M. Venous thromboembolism. Cardium Study: a pharmacor service. 2012. Burlington. MA: Decision Resources. http://decisionresources.com/Products-and-Services/Report?r=pcorcv0412. The report was received on February 11, 2012.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013;16:e1-5
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007;92:199-205
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8
   PubMed Web of Science ®Google Scholar
• Linkins L, O'Donnell M, Julian JA, et al. Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost 2010;8:2201-7
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2007. September 28, 2011. National Vital Statistics Reports; No. 59, No. 9. 9. Hyattsville, MD: National Center for Health Statistics. 2011. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_09.pdf. Accessed July 31, 2012
   Google Scholar
• Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. J Med Care 2005;43:1078-86
   PubMed Web of Science ®Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997;4:49-56
   PubMed Web of Science ®Google Scholar
• Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. J Thromb Haemost 2004;92:1336-41
   Google Scholar
• van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. J Lancet Neurol 2010;9:167-76
   PubMed Web of Science ®Google Scholar
• Xie J, Wu EQ, Zheng ZJ, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke J Cereb Circ 2006;37:2567-72
   Google Scholar
• Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001;111:130-9
   PubMed Web of Science ®Google Scholar
• National statistics - principal diagnosis only. Outcomes by ICD-9-CM diagnosis codes. Rockville, MD: Agency for Healthcare Research and Quality. 2012. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed August 31, 2012
   Google Scholar
• Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interventional Radiology 2006;17:449-59
   PubMed Web of Science ®Google Scholar
• AnalySource. AnalySource online: the online resource for drug pricing and deal information [online]. Available from http://www.analysource.com. Accessed January 3, 2013
   Google Scholar
• Red Book. Truven Health Analytics: Average Wholesale Price (AWP) [online]. Available from http://sites.truvenhealth.com/redbook/index.html. Accessed October 18, 2012
   Google Scholar
• Consumer Price Index, All Urban Consumers, Medical care -- Not Seasonally Adjusted. Washington, DC: United States Bureau of Labor Statistics. 2012. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed August 12, 2012
   Google Scholar
• The EINSTEIN PE Investigators. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism. The EINSTEIN PE Study. Bayer HealthCare and Janssen Research & Development, 2012
   Google Scholar
• The EINSTEIN DVT Investigators. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis: The EINSTEIN DVT Study. Bayer HealthCare & Ortho McNeil Pharmaceuticals, 2010
   Google Scholar
• Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-6; discussion 526-7
   PubMed Web of Science ®Google Scholar
• Perez-de-Llano LA, Leiro-Fernandez V, Golpe R, et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagul Fibrinolysis 2010;21:744-9
   PubMed Web of Science ®Google Scholar
• Beckman JA, Dunn K, Sasahara AA, et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 2003;89:953-8
   PubMed Web of Science ®Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-8
   PubMed Web of Science ®Google Scholar
• Cios DA, Baker WL, Sander SD, et al. Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. Am J Health Syst Pharm 2009;66:916-25
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• American Medical Association. CodeManager Online: Average 2011 Medicare's relative value payment amounts for CPT codes. 99201--99205, 99211--99215, 93970--93971, 71275, 71010, 71015, 71020--71023, 71030, 71034, 71035, 93005, 93010, 37191, 37193, 30901. Atlanta, GA: American Medical Association. 2011. https://commerce.ama-assn.org/ocm/index.jsp. Accessed August 31, 2012
   Google Scholar
• Professional Services Fee Schedule - Medicine Fees (2011) for CPT code 99601. Olympia, WA: Washington State Department of Labor & Industries. 2011. http://www.lni.wa.gov/ClaimsIns/Providers/Billing/FeeSched/2011/default.asp. Accessed September 4, 2012
   Google Scholar
• Clinical Diagnostic Laboratory Fee Schedule for the CPT code 85610. Baltimore, MD: Centers for Medicare & Medicaid Services. 2012. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed September 4, 2012
   Google Scholar
• National Health Care Expenses in the U.S. Civilian Non-institutionalized Population, 2009. Statistical Brief # 355. Rockville, MD: Agency for Healthcare Research and Quality. 2012. http://meps.ahrq.gov/mepsweb/data_files/publications/st355/stat355.pdf. Accessed September 4, 2012
   Google Scholar
• Lee WC, Christensen MC, Joshi AV, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007;23:57-65
   PubMed Web of Science ®Google Scholar
• Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74
   PubMed Web of Science ®Google Scholar